Jack Meehan

Stock Analyst at Barclays

(3.06)
# 1,376
Out of 5,044 analysts
137
Total ratings
69.51%
Success rate
21.33%
Average return

Stocks Rated by Jack Meehan

Labcorp Holdings
Oct 2, 2025
Maintains: Equal-Weight
Price Target: $275$290
Current: $259.69
Upside: +11.67%
Agilent Technologies
Feb 28, 2024
Maintains: Underweight
Price Target: $120$125
Current: $145.85
Upside: -14.30%
Waters
Aug 3, 2023
Maintains: Equal-Weight
Price Target: $275$288
Current: $345.95
Upside: -16.75%
Avantor
Mar 3, 2021
Initiates: Overweight
Price Target: $33
Current: $15.06
Upside: +119.12%
Illumina
Mar 3, 2021
Initiates: Underweight
Price Target: $325
Current: $97.80
Upside: +232.31%
InMode
Aug 17, 2020
Maintains: Overweight
Price Target: $18$19
Current: $15.28
Upside: +24.35%
Quest Diagnostics
Apr 23, 2020
Maintains: Equal-Weight
Price Target: $93$99
Current: $178.28
Upside: -44.47%
ICON Public Limited Company
Apr 23, 2020
Maintains: Overweight
Price Target: $170$180
Current: $177.73
Upside: +1.28%
Myriad Genetics
Mar 26, 2020
Maintains: Underweight
Price Target: $14$10
Current: $8.13
Upside: +23.08%
IQVIA Holdings
Mar 26, 2020
Maintains: Overweight
Price Target: $192$166
Current: $218.13
Upside: -23.90%
Maintains: Equal-Weight
Price Target: $51$43
Current: $74.01
Upside: -41.90%
Maintains: Equal-Weight
Price Target: $170$154
Current: $187.93
Upside: -18.05%
Maintains: Overweight
Price Target: $435$430
Current: $330.42
Upside: +30.14%
Maintains: Overweight
Price Target: $435$430
Current: $338.00
Upside: +27.22%
Downgrades: Equal-Weight
Price Target: n/a
Current: $28.19
Upside: -
Upgrades: Overweight
Price Target: $52$48
Current: $38.70
Upside: +24.03%
Upgrades: Equal-Weight
Price Target: $720$680
Current: $1,404.58
Upside: -51.59%
Maintains: Underweight
Price Target: $28$30
Current: $82.38
Upside: -63.58%
Maintains: Overweight
Price Target: $295$300
Current: $557.63
Upside: -46.20%
Initiates: Equal-Weight
Price Target: $40
Current: $1.44
Upside: +2,677.78%